Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Monday, June 15, 2026	**Time: 11:00 AM – 12:15 PM**						
Future Vigilance Approaches: What Data Sources Will Have the Biggest Impact on Patient Care?	1.25	0286-0000-26-510-L04-P	Knowledge	1.25	1.25		
Clinical Operations in Transition: Leadership Perspectives on AI, the Workforce, and the Future of Trial Execution	1.25	0286-0000-26-511-L04-P	Knowledge	1.25	1.25		
Evidence-Based Insights Informing Participant Compensation Strategies	1.25	0286-0000-26-512-L04-P	Knowledge	1.25	1.25		
Enhancing Regulatory Collaboration Through Cloud Technologies	1.25	0286-0000-26-513-L04-P	Knowledge	1.25	1.25		
AI Tools in Clinical Trials: Regulatory Considerations for Radiologic and Pathologic Assessment	1.25	0286-0000-26-514-L04-P	Knowledge	1.25	1.25		
The Great Debate: Using AI in Patient-Facing Materials	1.25	0286-0000-26-515-L04-P	Knowledge	1.25	1.25		
Combined Clinical Trials: A Focus on In Vitro Diagnostics	1.25	0286-0000-26-516-L04-P	Knowledge	1.25	1.25		
Managing What Matters: Turning Project Decisions Into Portfolio Impact in R&D and Medical	1.25	0286-0000-26-517-L04-P	Application	1.25	1.25	1.25	216647VJP8
Evolving Role of the Quality Professional: The Future of Professional Development in the Age of AI	1.25	0286-0000-26-518-L04-P	Knowledge	1.25	1.25	1.25	216641I1NS
Accelerating US Based Domestic Manufacturing by Leveraging Innovative Regulatory Concepts	1.25	0286-0000-26-519-L04-P	Knowledge	1.25	1.25		
Health Canada Town Hall	1.25	0286-0000-26-520-L04-P	Knowledge	1.25	1.25		
How the Upcoming FDA User Fee Legislation Could Advance Innovation and Reshape the Agency	1.25	0286-0000-26-521-L04-P	Knowledge	1.25	1.25		
Regulatory Cooperation Between the United States and Japan	1.25	0286-0000-26-522-L04-P	Knowledge	1.25	1.25		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
FDA Public Posting of Complete Response Letters: A Year in Review, Trends, and Impact Analysis	1.25	0286-0000-26-523-L04-P	Application	1.25	1.25		
Transforming Women's Health Science: Closing the Innovation Gap and Accelerating Impact	1.25	0286-0000-26-524-L04-P	Knowledge	1.25	1.25		
A Holistic Approach to Achieve Fit for Purpose Clinical Trial: Integrating a Function-Agnostic End-to-End Quality by Design and Risk-Based Quality Management Strategy	1.25	0286-0000-26-525-L04-P	Knowledge	1.25	1.25		

Monday, June 15, 2026 **Time: 2:30 PM – 3:30 PM**

Responsible Use of AI in Pharmacovigilance: Global Perspectives from CIOMS WG XIV	1.00	0286-0000-26-526-L04-P	Knowledge	1.00	1.00		
Insights Regarding Implementation of the ASAP Process	1.00	0286-0000-26-653-L04-P	Knowledge	1.00	1.00		
Industry Collaboration 2030: Head, Heart and Gut Perspectives	1.00	0286-0000-26-527-L04-P	Knowledge	1.00	1.00		
Expanding Access and Engagement: Lessons from Decentralized Clinical Trial Solutions	1.00	0286-0000-26-528-L04-P	Knowledge	1.00	1.00		
ICH M11 in Action: Digital Protocols, AI, and Cloud for Patient-Centered Regulatory Science	1.00	0286-0000-26-529-L04-P	Application	1.00	1.00		
Next-Generation Data Standards for RWD/RWE (FHIR, Dataset-JSON, and the Road Ahead)	1.00	0286-0000-26-530-L04-P	Knowledge	1.00	1.00		
AI Competency Framework for Medical Writers: Essential Skills to Enhance Medical Writing AI Expertise	1.00	0286-0000-26-531-L04-P	Knowledge	1.00	1.00		
Aligning Strategy with Execution: Leveraging Integrated Program Plans, Project, Program, and Portfolio Management, and AI to Advance Drug Development	1.00	0286-0000-26-532-L04-P	Application	1.00	1.00	1.00	21665YGZQV

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Opportunity, Caution or Reluctance: Global Trends for Regulating AI in Pharmaceutical Manufacturing	1.00	0286-0000-26-533-L04-P	Application	1.00	1.00		
Harnessing International Regulatory Reliance and Collaboration to Accelerate Innovation and Patient Access to Medicines	1.00	0286-0000-26-534-L04-P	Knowledge	1.00	1.00		
The State of Artificial Intelligence in Regulatory Review and Decision-Making: Perspectives from FDA, EMA, PMDA, and CDE	1.00	0286-0000-26-535-L04-P	Knowledge	1.00	1.00		
Early Intervention in Slowly Progressing Chronic Diseases: Navigating Regulatory and Reimbursement Uncertainty	1.00	0286-0000-26-536-L04-P	Application	1.00	1.00		
A Conversation About Quality: A Global Regulators Discussion	1.00	0286-0000-26-537-L04-P	Knowledge	1.00	1.00		
The Quality Blueprint: How Cross-Functional Leadership and Employee Ownership Drive Clinical Trial Excellence	1.00	0286-0000-26-538-L04-P	Knowledge	1.00	1.00		
Driving Efficiency in Clinical Development with Master Protocols	1.00	0286-0000-26-539-L04-P	Application	1.00	1.00		

Monday, June 15, 2026 **Time: 4:00 PM – 5:00 PM**

Tailoring Risk Minimization Activities to Special Populations Locally: Patient Needs, Digitalization, Global Learning	1.00	0286-0000-26-540-L04-P	Knowledge	1.00	1.00		
DIA2026-001: Co-Creating the Patient-Centric Trial Live	1.00	0286-0000-26-541-L04-P	Application	1.00	1.00		
Enabling Faster Multi-Regional Study Start-Up Through Harmonization and Collaboration	1.00	0286-0000-26-542-L04-P	Application	1.00	1.00		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Study Participants Want to Know When AI is Processing Their Medical Data: Perceptions of AI and Operational Implications	1.00	0286-0000-26-543-L04-P	Knowledge	1.00	1.00		
Accelerating Regulatory Readiness: A Vision for AI-Enabled Pandemic Preparedness	1.00	0286-0000-26-544-L04-P	Knowledge	1.00	1.00		
Medical Writing Ted Experience	1.00	0286-0000-26-545-L04-P	Knowledge	1.00	1.00		
Race/Ethnicity, Ancestry, and Clinical Phenotype Real-World Data to Precisely Anticipate Treatment Effectiveness and Patient Outcomes	1.00	0286-0000-26-546-L04-P	Knowledge	1.00	1.00		
Mentorship Myth Busters: Moving Beyond Misconceptions	1.00	0286-0000-26-547-L04-P	Knowledge	1.00	1.00	1.00	2166DNFT53
Navigating CMC Challenges for Innovative Cell and Gene Therapy Products: From Starting Materials to Comparability	1.00	0286-0000-26-576-L04-P	Knowledge	1.00	1.00		
Understanding the Misconceptions and Myths Around Surrogate Endpoints	1.00	0286-0000-26-548-L04-P	Knowledge	1.00	1.00		
Middle East Town Hall: The Rising Global Innovation Hub - Aligning Regulations and Unlocking Fresh Opportunities	1.00	0286-0000-26-549-L04-P	Knowledge	1.00	1.00		
Accelerating Pediatric Innovation: Leveraging Extrapolation and Global Policy to Transform Drug Development for Children	1.00	0286-0000-26-550-L04-P	Knowledge	1.00	1.00		
Japan Town Hall	1.00	0286-0000-26-551-L04-P	Knowledge	1.00	1.00		
Regulatory and Industry Perspectives: Understanding the Significance and Impact of GCP Inspection Observations	1.00	0286-0000-26-552-L04-P	Knowledge	1.00	1.00		
Is There an Urgent Need for Global Alignment on External Controls in Clinical Trials?	1.00	0286-0000-26-553-L04-P	Application	1.00	1.00		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Bias and Methodological Challenges in External Control Arms Addressing Time-Related Bias, Endpoint Alignment, Unmeasured Confounding	1.00	0286-0000-26-554-L04-P	Knowledge	1.00	1.00		

Tuesday, June 16, 2026 **Time: 10:15 AM – 11:30 AM**

From Conventional to Intelligent: Redefining Pharmacovigilance with AI and Global Collaboration	1.25	0286-0000-26-555-L04-P	Knowledge	1.25	1.25		
From Barriers to Bridges: Unlocking Research Potential in Primary Care	1.25	0286-0000-26-556-L04-P	Application	1.25	1.25		
Paying Fair: Regulatory and Ethical Challenges in Research Participant Compensation	1.25	0286-0000-26-557-L04-P	Application	1.25	1.25		
Agility Unlocked: How Mixed FSP/FSO Models Enhance Efficiency and Facilitate the Transition from FSO to FSP Outsourcing	1.25	0286-0000-26-558-L04-P	Knowledge	1.25	1.25		
Integrating Artificial Intelligence and Real-World Evidence: FDA's Framework for Advancing Medical Product Development	1.25	0286-0000-26-559-L04-P	Knowledge	1.25	1.25		
How Standardized Protocol Data Plus AI Power Patient Centric Studies	1.25	0286-0000-26-560-L04-P	Application	1.25	1.25		
AI Risk Scores and Regulatory Forks: Diagnose Your Software's Regulatory Fate	1.25	0286-0000-26-561-L04-P	Application	1.25	1.25		
Enhanced Analytical Procedure Development: Principles, Prior Knowledge, and Change Management	1.25	0286-0000-26-562-L04-P	Application	1.25	1.25		
Modernizing Nonclinical Safety Assessment: FDA and EMA Roadmaps to Reduce Animal Testing	1.25	0286-0000-26-563-L04-P	Knowledge	1.25	1.25		
Innovation Gridlock: When Misaligned Policies Threaten Progress for Patients	1.25	0286-0000-26-564-L04-P	Knowledge	1.25	1.25		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Advancing Chronic Disease Development: Insights from FDA, EMA, PMDA, CDE and other Global Regulators	1.25	0286-0000-26-565-L04-P	Knowledge	1.25	1.25		
Leveraging Federated AI and Open Data to Transform Oncology Research and Development	1.25	0286-0000-26-566-L04-P	Knowledge	1.25	1.25		
Next Generation Clinical Trial Quality Assurance Using Advanced Analytics	1.25	0286-0000-26-567-L04-P	Knowledge	1.25	1.25		
Patient Registries: Basket Trial or Basket Case?	1.25	0286-0000-26-568-L04-P	Knowledge	1.25	1.25		

Tuesday, June 16, 2026 **Time: 1:45 PM – 3:00 PM**

Suffix or Superfluous? Evaluating FDA's Biologics Naming Convention	1.25	0286-0000-26-569-L04-P	Knowledge	1.25	1.25		
The Synthetic AI Patient Persona: Augmenting Patient Centricity in Clinical Trials	1.25	0286-0000-26-570-L04-P	Knowledge	1.25	1.25		
Tolerability in Immuno-Oncology: Patient Experience as a Core Element of Clinical Trials	1.25	0286-0000-26-571-L04-P	Knowledge	1.25	1.25		
Early Outcomes and Strategic Learnings from the DIA Obesity Consortium's Initial Collaborative Phase	1.25	0286-0000-26-654-L04-P	Knowledge	1.25	1.25		
Applied Innovation for Patients: Implementing AI, Cloud, and Data in Regulatory Science	1.25	0286-0000-26-572-L04-P	Knowledge	1.25	1.25		
Is Your AI Ready to Scale? Build the Governance Backbone for Reliable Innovation and Trust	1.25	0286-0000-26-573-L04-P	Knowledge	1.25	1.25		
Unlock AI's Full Potential: The Power of FAIR Data	1.25	0286-0000-26-574-L04-P	Application	1.25	1.25		
Project Management as a Catalyst for Enterprise Transformation	1.25	0286-0000-26-575-L04-P	Knowledge	1.25	1.25	1.25	21662N25CW
Labeling as a Strategic Asset: Advancing Patient Voice and Creating Value Through Meaningful Product Communication	1.25	0286-0000-26-577-L04-P	Application	1.25	1.25		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Regulators Approach to Address Drug Shortages	1.25	0286-0000-26-578-L04-P	Knowledge	1.25	1.25		
Innovations in Drug Review: A Global Perspective	1.25	0286-0000-26-579-L04-P	Application	1.25	1.25		
Quality by Design Revolution: Is There Still a Place for Traditional Clinical Trial Functions?	1.25	0286-0000-26-580-L04-P	Knowledge	1.25	1.25		
Taiwan Town Hall: Strategies to Promote Medicine Supply Resilience	1.25	0286-0000-26-669-L04-P	Knowledge	1.25	1.25		
EMA Town Hall	1.25	0286-0000-26-670-L04-P	Knowledge	1.25	1.25		
Global Regulatory Perspectives on Bayesian Design and Analysis Informing Regulatory Decision Making	1.25	0286-0000-26-581-L04-P	Knowledge	1.25	1.25		

Tuesday, June 16, 2026 **Time: 4:15 PM – 5:15 PM**

Increasing Vigilance Transparency: When is the Right Time to Publish Safety Signals?	1.00	0286-0000-26-582-L04-P	Knowledge	1.00	1.00		
Reimagining Site Source: Optimizing Clinical Trial Execution for Sponsors, Sites, and Patients	1.00	0286-0000-26-583-L04-P	Knowledge	1.00	1.00		
Clinical Research Training for Community Cancer Centers: A Pilot to Extend Clinical Trials into Diverse Catchment Areas	1.00	0286-0000-26-584-L04-P	Knowledge	1.00	1.00		
Operationalizing Large Language Models in Drug Development	1.00	0286-0000-26-585-L04-P	Knowledge	1.00	1.00		
Evolving Artificial Intelligence Regulatory Landscape in Drug Development Across US and EU	1.00	0286-0000-26-586-L04-P	Application	1.00	1.00		
Optimizing the Content Ecosystem Through Lean Authoring: A Framework to Meet Regulatory Expectations and Prepare to Automate	1.00	0286-0000-26-587-L04-P	Knowledge	1.00	1.00		
Latest in Combination Product Industry Trends: Development and Submission Strategies for Success	1.00	0286-0000-26-588-L04-P	Knowledge	1.00	1.00		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Adapting Regulatory Frameworks to Address Mass Distribution of Unapproved or Unauthorized Medicines	1.00	0286-0000-26-589-L04-P	Knowledge	1.00	1.00		
Novel Endpoints, Biomarkers, and Digital Tools: Strategies for Regulatory Acceptance and Scientific Alignment	1.00	0286-0000-26-590-L04-P	Application	1.00	1.00		
Advancing Global Regulatory Harmonization for Cell and Gene Therapies: Enhancing Access and Innovation	1.00	0286-0000-26-591-L04-P	Application	1.00	1.00		
China Town Hall	1.00	0286-0000-26-592-L04-P	Knowledge	1.00	1.00		
Advancing Pediatric Drug Development in Asia through Real-World Evidence and Regulatory Innovation	1.00	0286-0000-26-593-L04-P	Application	1.00	1.00		
Access Consortium Town Hall	1.00	0286-0000-26-594-L04-P	Knowledge	1.00	1.00		
Unlocking Transformative Value: AI and Advanced Analytics in Good Clinical Practice and Good Pharmacovigilance Practice Quality Assurance	1.00	0286-0000-26-595-L04-P	Knowledge	1.00	1.00		
Leveraging Real-World Evidence and External Controls in Clinical Trials of Rare Outcomes/Diseases: Statistical Innovation and Novel Applications	1.00	0286-0000-26-596-L04-P	Application	1.00	1.00		
Oncology Pathways Under Pressure: From CAR-T Access Today to Longevity-Driven Care Tomorrow	1.00	0286-0000-26-655-L04-P	Application	1.00	1.00		

Wednesday, June 17, 2026 **Time: 10:15 AM – 11:30 AM**

From Guidance to Practice: Regulatory and Stakeholder Views on Evaluating Risk Minimization Measures	1.25	0286-0000-26-597-L04-P	Knowledge	1.25	1.25		
Case Studies on AI-Enabled and Analytical Practices and Solutions Reducing Site and Participant Burden in Clinical Trials	1.25	0286-0000-26-598-L04-P	Application	1.25	1.25		
Counting the Cost: Translating Participant Burden into Fair Compensation	1.25	0286-0000-26-599-L04-P	Application	1.25	1.25		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Preparing for the Future: From EU Legislative Reform to Digital Transformation and AI-Driven Efficiencies	1.25	0286-0000-26-600-L04-P	Knowledge	1.25	1.25		
Enhancing Clinical Trial Oversight: Using Statistical Outlier Detection with Generative AI for Protocol Deviation Analysis	1.25	0286-0000-26-601-L04-P	Knowledge	1.25	1.25		
Bridging the AI Divide: Regulatory Trends, Industry Innovation, and the Future of AI in Pharma & Biotech	1.25	0286-0000-26-602-L04-P	Application	1.25	1.25		
Decision Under Uncertainty	1.25	0286-0000-26-603-L04-P	Application	1.25	1.25	1.25	2166LODLKY
From Dysfunctions to Dynamics: Mapping Hidden Assumptions to Strengthen Trust, Debate, and Accountability	1.25	0286-0000-26-604-L04-P	Application	1.25	1.25	1.25	2166GIDLXI
Can You Complete Your Submission in 10 Weeks?	1.25	0286-0000-26-605-L04-P	Knowledge	1.25	1.25	1.25	2166B0UIY1
Future of Enhanced Product Development: Enabled Through New ICH Guidelines	1.25	0286-0000-26-606-L04-P	Application	1.25	1.25		
Navigating the FDA Commissioner's National Priority Voucher Program: Implementation Insights and Strategic Impact	1.25	0286-0000-26-607-L04-P	Application	1.25	1.25		
International Regulatory Cooperation with the African Medicines Agency	1.25	0286-0000-26-608-L04-P	Knowledge	1.25	1.25		
FDA Rare Disease Town Hall	1.25	0286-0000-26-609-L04-P	Knowledge	1.25	1.25		
Achieving Regulatory-Grade Pragmatism in Streamlined Trials Embedded in Clinical Practice	1.25	0286-0000-26-610-L04-P	Application	1.25	1.25		
Indonesia's Clinical Trial Transformation: One Year of Coordinated Regulatory Reform	1.25	0286-0000-26-656-L04-P	Knowledge	1.25	1.25		
How to Accelerate Utilization of Decentralized Clinical Trial: What are Issues to Perform Decentralized Clinical Trial?	1.25	0286-0000-26-611-L04-P	Knowledge	1.25	1.25		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Wednesday, June 17, 2026		**Time: 1:45 PM – 2:45 PM**					
Pharmacovigilance to Strengthen Vaccine Confidence and Address Hesitancy: Lessons from Brazil and Beyond	1.00	0286-0000-26-612-L04-P	Knowledge	1.00	1.00		
Optimizing Protocol Data Collection to Reduce Site and Patient Participation Burden	1.00	0286-0000-26-613-L04-P	Application	1.00	1.00		
Designing the Future: Emulation of Clinical Trials Using Real-World Data	1.00	0286-0000-26-614-L04-P	Knowledge	1.00	1.00		
Patient-Directed Data Sharing: Enabling Innovations While Including Patients in Decisions About Secondary Data Use	1.00	0286-0000-26-615-L04-P	Knowledge	1.00	1.00		
Navigating the Regulatory Labyrinth: How Well Do Language Models Read the Fine Print?	1.00	0286-0000-26-616-L04-P	Knowledge	1.00	1.00		
Building AI Governance Frameworks: Classification, Validation and Regulatory Alignment in Life Sciences	1.00	0286-0000-26-618-L04-P	Application	1.00	1.00		
Beyond the Keyboard: Elevating Regulatory Writing with a Business Mindset	1.00	0286-0000-26-619-L04-P	Knowledge	1.00	1.00		
Streamlining Regulatory Frameworks for Complex Generic Development: Global Extractables and Leachables Harmonization	1.00	0286-0000-26-620-L04-P	Application	1.00	1.00		
Bold Leadership: Embolden Your Team for Smart Risk-Taking	1.00	0286-0000-26-621-L04-P	Application	1.00	1.00	1.00	21663K6JS3
Program Manager: Jack of All Trades, Master of None?	1.00	0286-0000-26-622-L04-P	Knowledge	1.00	1.00	1.00	21668R8O1J
Access Unlocked: Collaborative Strategies for Navigating Regulatory and Payor Landscapes	1.00	0286-0000-26-623-L04-P	Knowledge	1.00	1.00		
The Next Frontier: Autoimmune Cell & Gene Therapy, Regulation, and Patient Access	1.00	0286-0000-26-625-L04-P	Knowledge	1.00	1.00		
MHRA Town Hall	1.00	0286-0000-26-626-L04-P	Knowledge	1.00	1.00		
Destigmatizing 483 Observations	1.00	0286-0000-26-627-L04-P	Knowledge	1.00	1.00		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Real-World Evidence Throughout the Product Life Cycle: Case Studies and Real-Life Examples	1.00	0286-0000-26-628-L04-P	Knowledge	1.00	1.00		

Wednesday, June 17, 2026 **Time: 4:00 PM – 5:00 PM**

Utilizing Signal Detection Methodologies: A Toolkit for Diverse Product Types	1.00	0286-0000-26-629-L04-P	Knowledge	1.00	1.00		
50,000 Participants, Two Countries, One DCT: Oversight That Worked	1.00	0286-0000-26-630-L04-P	Application	1.00	1.00		
Clinical Trial Experience Surveys: Sponsor Wide Implementation Across Countries and Therapy Areas	1.00	0286-0000-26-631-L04-P	Application	1.00	1.00		
Not Can, but Should: How do we WANT AI/ML to Transform Clinical Development?	1.00	0286-0000-26-632-L04-P	Knowledge	1.00	1.00		
Accelerating AI-Enabled Drug Discovery and Development with Federated Computing	1.00	0286-0000-26-633-L04-P	Knowledge	1.00	1.00		
Medical Affairs: Drivers of Scientific Impact and Strategic Value in Healthcare	1.00	0286-0000-26-634-L04-P	Knowledge	1.00	1.00		
Who Owns Long-Term Follow-Up? Addressing Stakeholder Gaps in Gene Therapy Evidence Generation	1.00	0286-0000-26-635-L04-P	Knowledge	1.00	1.00		
Leading for Growth: Unlocking Individual Potential in Your Team	1.00	0286-0000-26-657-L04-P	Application	1.00	1.00	1.00	2166FWL0S0
Regulatory CMC and Product Quality Hot Topics Discussion	1.00	0286-0000-26-636-L04-P	Knowledge	1.00	1.00		
Benefit-Risk Planning: Implementing Benefit-Risk Guidelines from FDA and CIOMS XII Across the Product Lifecycle	1.00	0286-0000-26-637-L04-P	Application	1.00	1.00		
Navigating the New FDA: Insights from Former FDA Chief of Staffs	1.00	0286-0000-26-638-L04-P	Knowledge	1.00	1.00		
India Town Hall: India's Evolving Regulatory Landscape - Policy Reforms and Digital Systems Accelerating Innovation	1.00	0286-0000-26-639-L04-P	Knowledge	1.00	1.00		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
Navigating the New US and EU Rare Disease Regulatory Framework and Global Harmonization Efforts	1.00	0286-0000-26-640-L04-P	Knowledge	1.00	1.00		
Navigating the Rules of Innovation: Regulatory Expectations for Generative AI Use Cases	1.00	0286-0000-26-641-L04-P	Knowledge	1.00	1.00		
Real World Evidence in Regulatory Decision-Making: Challenges, Innovations, and Impact	1.00	0286-0000-26-642-L04-P	Knowledge	1.00	1.00		
Anvisa Townhall - From Backlogs to Breakthroughs: Building a Smarter Regulatory Future	1.00	0286-0000-26-666-L04-P	Knowledge	1.00	1.00		

Thursday, June 18, 2026 **Time: 8:00 AM – 9:00 AM**

No Report Left Behind: Human-Centered Safety Reporting	1.00	0286-0000-26-643-L04-P	Knowledge	1.00	1.00		
Cross-Functional Agentic End-to-End Dossier Preparation: Where Are We Today and Progress Towards Realizing the Vision	1.00	0286-0000-26-644-L04-P	Knowledge	1.00	1.00		
How RA/QA Leaders Can Optimize AI and Reduce Risk as Industry Moves from the Wild West to its Inevitable Second Phase - Categorization	1.00	0286-0000-26-645-L04-P	Application	1.00	1.00		
The View from the Top: What is the Future of Medical Writing?	1.00	0286-0000-26-646-L04-P	Knowledge	1.00	1.00		
Patient Preference Studies in Clinical Trial Design and Submissions: Enhancing Patient-Centricity with Insights from ICH E22	1.00	0286-0000-26-624-L04-P	Knowledge	1.00	1.00		
Fighting Medical Disinformation (Without Actually Starting a Fight)	1.00	0286-0000-26-647-L04-P	Application	1.00	1.00	1.00	2166KJ1ZXS
AI-Enabled Structured CMC Submissions: Leveraging Cloud Technology for Enhanced Collaboration and Analysis	1.00	0286-0000-26-648-L04-P	Application	1.00	1.00		

Session Title	ACPE	UAN	Activity Type	CME	RN	PMI	PDU#
PV Compliance DIY: How to Find and Fix Quality Issues Before They Find You	1.00	0286-0000-26-649-L04-P	Knowledge	1.00	1.00		
Regulatory and Industry Perspectives on Good Clinical Practice Inspections: Regulatory Approaches, Industry Impact, and Future Harmonization Opportunities	1.00	0286-0000-26-650-L04-P	Knowledge	1.00	1.00		
EMA – FDA Question Time	1.00	0286-0000-26-667-L04-P	Knowledge	1.00	1.00		
Singapore Town Hall	1.00	0286-0000-26-668-L04-P	Knowledge	1.00	1.00		
Role of External Data in Confirmatory Clinical Trial: Current Landscape and Future Perspectives	1.00	0286-0000-26-651-L04-P	Knowledge	1.00	1.00		

Thursday, June 18, 2026 **Time: 9:30 AM – 10:30 AM**

FDA Town Hall	1.00	0286-0000-26-652-L04-P	Knowledge	1.00	1.00		